Edwards Lifesciences (EW) provided guidance Wednesday for 2025.
The the medical technology company said it expects full-year adjusted earnings per share of $2.40 to $2.50 on sales of $5.6 billion to $6.0 billion.
Analysts polled by Factset expect non-GAAP EPS of $2.45 on sales of $5.91 billion.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。